Evidence map›Paper›PMID 42321962›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling.

Shengnan Zhang, Nan Yang, Ruwei Yang, Yuanfang Qin, Tingting Wu, Cuifang Wu, Yueliang Xie, Jingjing Liu, Chun Liu, Qi Pei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shengnan ZhangDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0009-0007-4837-1969
Nan YangDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0009-0007-4840-1072
Ruwei YangDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Yuanfang QinDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Tingting WuDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Cuifang WuDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Yueliang XieDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Jingjing LiuDepartment of Intensive Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Chun LiuDepartment of Respirology & Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Qi PeiDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-6711-4251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous polymyxin B (PMB) is widely used for treating drug-resistant gram-negative pneumonia, though its efficacy in pulmonary infections is considered limited. This study aims to identify patients with severe pulmonary infections suitable for treatment with intravenous PMB alone and to recommend individualized optimal dosing regimens. Physiologically based pharmacokinetic (PBPK) models, developed using data from mice, healthy subjects, and critically ill patients, were employed to predict PMB concentrations in epithelial lining fluid (ELF) and plasma. All models were validated against published pharmacokinetic data, and Monte Carlo simulations were used to evaluate various dosing regimens. The therapeutic target was defined as an ELF steady-state 24 h area under the concentration-time curve to minimum inhibitory concentration (AUC

Indexed as

Anti-Bacterial AgentsModels, BiologicalPolymyxin BAdministration, IntravenousAdultAgedAnimalsArea Under CurveCritical IllnessDose-Response Relationship, DrugFemaleHumansMaleMiceMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial AgentsPolymyxin Bintravenous administrationminimum inhibitory concentrationphysiologically based pharmacokinetic modelingPK/PDpolymyxin Bpulmonary infection

Identifiers

PMID42321962
PMCPMC13282184

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.